Precision Medicine in NSCLC With Rare Mutations: Pinpointing the Right Treatment for the Right Patient at the
Right Time
Release Date: April 30, 2019
Last Reviewed: April 27, 2019
Expiration Date: April 30, 2020
Time to Complete Activity: 1.0 hour

*This activity expired for credit on April 30, 2020 and is no longer available for credit

NEW UPDATE POST ACTIVITY LAUNCH: The FDA has recently approved entrectinib for the treatment of adult patients with ROS1-positive metastatic NSCLC. An accelerated approval was also granted to entrectinib for the treatment of adult and adolescent patients with solid tumors harboring an NTRK gene fusion and who have no alternative effective therapies available.
FDA News Release. FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. FDA also approves drug for second indication in a type of lung cancer. Accessed 8/16/19.  
Mark M. Awad, MD, PhD
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Alexander Drilon, MD
Clinical Director
Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, NY
This activity is provided by Paradigm Medical Communications, LLC. 
Target Audience
This activity has been designed to address the educational needs of medical oncologists and pathologists. It will also be of benefit to interventional radiologists, pulmonologists, surgical oncologists, thoracic surgeons, and other healthcare providers involved in the management of non-small cell lung cancer, including oncology nurses, nurse practitioners, and PAs.
Statement of Need
In this era of personalized medicine in which the identification of targetable genetic alterations will help determine appropriate treatment in patients with non-small cell lung cancer (NSCLC), oncology clinicians, along with pathologists, require new insights into the specific techniques that are being used to identify the targets and then to select the specific treatment(s) that correspond to these targets. In NSCLC, recent advances have made it possible to analyze tumor oncogenes for genetic mutations that can contribute to the development of metastatic disease and there are several treatments that are now associated with these targets. With these new developments, oncology clinicians need to become well versed in this new approach to testing for these targets as well as the mechanisms of action for the corresponding treatments that are now available.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Identify the types of genetic mutations found in non-small cell lung cancer and associated guideline recommendations for treatment
  • Evaluate clinical trial data for new and emerging targeted treatments in non-small cell lung cancer with genetic mutations
  • Summarize the recommendations regarding initial and repeat biomarker testing for genetic mutations in non-small cell lung cancer
  • Introduction
  • Recommendations for Genetic Testing
  • Genetic Markers Associated With NSCLC
    • Targeted Therapies for Genetic Alterations
  • Newer Therapies: Current and Ongoing Late-Phase Trial Data
  • Case Studies
  • Resources on NSCLC
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Instructions for Participation
To receive a CME certificate of participation, you should:
  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5. As you navigate the application using the supplied controls, the slides will present information via video, audio, text, images, or tables.
Supported Browsers:
For Desktops (Windows/Mac/Linux)
Internet Explorer 10 or higher, Firefox 28 or higher, Safari 9 or higher, Google Chrome 45 or higher, Opera 30 or higher
For Tablets or Mobile (iPad/Android/Surface)
iOS Safari 9 or higher, Android 4.4 or higher, IE Mobile 12 or higher
Technical Support: If you have any technical problems or playback issues email us at
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Mark M. Awad, MD, PhD
Grant/Research Support: AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.
Retained Consultant: AstraZeneca; Blueprint Medicine; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co.; Inc, Pfizer Inc.; Syndax
Alexander Drilon, MD
Retained Consultant: AstraZeneca; Bayer Healthcare; BeiGene; Blueprint Medicine Corporation; Exelixis, Inc.; Genentech, Inc./Roche; Helsinn Therapeutics; Hengrui Therapeutics Inc.; Ignyta; Loxo Oncology; Pfizer Inc.; TP Therapeutics, Inc.; Takeda Pharmaceutical Company Ltd.
Honoraria: AstraZeneca; Bayer Healthcare; Foundation Medicine, Inc; Genentech, Inc./Roche; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicians Education Resources; Research to Practice; Targeted Oncology; Tyra Biosciences
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities located at (herein referred to as “website"). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits that participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at
© 2019 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.